Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.49 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.49 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CD69 | Q07108 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | PTPRB | P23467 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14883883 | 0.87 | KDM4E (0.51) | CSNK2A2CSNK2BCSNK2A1MCL1MAPT | |
| SCHEMBL2058911 | 0.86 | THRA (0.47) | MCL1CD69HPGDPTPRBHSD17B10 | |
| SCHEMBL14931907 | 0.84 | MCL1 (0.45) | CSNK2A2CSNK2BCSNK2A1MCL1CD69 | |
| SCHEMBL8240454 | 0.84 | MCL1 (0.45) | MCL1CD69HPGDPTPRBHSD17B10 | |
| SCHEMBL11570516 | 0.84 | KDM4E (0.55) | MCL1MAPTHPGDKMT2AKDM4E | |
| SCHEMBL3201351 | 0.84 | KMT2A (0.55) | MCL1CD69HPGDPTPRBHSD17B10 | |
| SCHEMBL2059557 | 0.84 | AGBL2 (0.46) | MCL1CD69HPGDPTPRBHSD17B10 | |
| SCHEMBL14997055 | 0.83 | MAPT (0.47) | MAPTHPGDHSD17B10KMT2AKDM4E | |
| SCHEMBL11332162 | 0.82 | HSD17B10 (0.46) | MCL1CD69HPGDPTPRBHSD17B10 | |
| SCHEMBL6165860 | 0.82 | HSD17B10 (0.56) | MCL1CD69HPGDPTPRBHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2890677-B1 | N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2017-11-15 | — | — | EP | disclosed |
| US-9447083-B2 | N-acylhydrazone derivatives for selective T cell inhibitor and anti-lymphoid malignancy drug | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2016-09-20 | — | — | US | disclosed |
| US-20150252030-A1 | N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2015-09-10 | — | — | US | disclosed |
| EP-2890677-A1 | N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG | Chong Kun Dang Pharmaceutical Corp. (KR) | 2015-07-08 | — | — | EP | disclosed |
| US-8975411-B2 | Therapeutic agent for neurological diseases | NEUGEN PHARMA INC. (JP) | 2015-03-10 | — | — | US | disclosed |
| EP-2599776-B1 | THERAPEUTIC AGENT FOR NEUROLOGICAL DISEASES | NEUGEN PHARMA INC (JP) | 2014-10-15 | — | — | EP | disclosed |
| WO-2014035149-A1 | N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2014-03-06 | — | — | WO | disclosed |
| US-20130190363-A1 | THERAPEUTIC AGENT FOR NEUROLOGICAL DISEASES | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2013-07-25 | — | — | US | disclosed |
| EP-2599776-A1 | THERAPEUTIC AGENT FOR NEUROLOGICAL DISEASES | Neugen Pharma Inc. (JP) | 2013-06-05 | — | — | EP | disclosed |
| US-7968707-B2 | Reacting an amino, hydroxy substituted amide with a heterocyclic substituted carboxylic acid to produce (2S,3S,5S)-2-(2,6-Dimethylphenoxyacetyl) amino-3-hydroxy-5-[2S-1-imidazolidin-2-onyl)-3-methyl-butanoyl] amino-1,6-diphenylhexane; inhibitors of HIV infection | ABBOTT LABORATORIES (US) | 2011-06-28 | — | — | US | disclosed |
| CN-1314906-A | Salts of paroxetine | SMITHKLINE BEECHAM PLC (GB) | 2001-09-26 | — | — | CN | disclosed |
| US-6284767-B1 | AIDS; MIXTURE WITH ENZYME INHIBITOR | ABBOTT LABORATORIES | 2001-09-04 | — | — | US | disclosed |
| US-5914332-A | NOVEL COMPOUNDS FOR USE AS HIV PROTEASE INHIBITORS IN TREATING HIV AND AIDS | ABBOTT LABORATORIES (US) | 1999-06-22 | — | — | US | disclosed |
| US-5905068-A | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1999-05-18 | — | — | US | disclosed |
| EP-0882024-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | Abbott Laboratories (US) | 1998-12-09 | — | — | EP | disclosed |
| EP-0876353-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | Abbott Laboratories (US) | 1998-11-11 | — | — | EP | disclosed |
| WO-1997021683-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1997-06-19 | — | — | WO | disclosed |
| WO-1997021685-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1997-06-19 | — | — | WO | disclosed |
| US-4672065-A | TOMATO LATE BLIGHT | CHEVRON RESEARCH COMPANY (US) | 1987-06-09 | — | — | US | disclosed |
| US-4535087-A | FOR TOMATO LATE BLIGHT | CHEVRON RESEARCH COMPANY (US) | 1985-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190363-A1 | THERAPEUTIC AGENT FOR NEUROLOGICAL DISEASES | AIFM1, AIFM2, GPX4 | CSNK2A2 709/4885CSNK2B 1095/4885CSNK2A1 688/4885 |
| US-20150252030-A1 | N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG | MALT1, MCL1, ACIN1 | CSNK2A2 1380/4885CSNK2B 924/4885CSNK2A1 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.